Rabab Nasrallah

Principle at Earlybird Venture Capital

Speaker

Dr. Rabab Nasrallah is a Principal at Earlybird Venture Capital. She currently serves as a board member of Grey Wolf Therapeutics and as a board observer for ImCheck Therapeutics, Argá Medtech, Priothera, and Prothea Technologies. Rabab has worked in prestigious research institutions, including The George Institute for Global Health, Lowy Cancer Research Centre, Cancer Research UK, and Cambridge University. She holds a PhD in regenerative medicine from UNSW Sydney and Cancer Research UK Manchester Institute. Additionally, she has completed a postdoctoral fellowship at the Babraham Institute in Cambridge, focusing on therapeutics in the immuno-oncology and autoimmune disease space.